EU Review of Pharmaceutical Incentives: Recommendations for Change
In 2016, the European Council decided it was time for a review of the incentives that the EU provides to companies that develop new...
Time for new pharmaceutical-innovation models
The pharmaceutical industry is one of the most profitable on earth, expected to be worth $1.4 trillion by the end of 2020. Last year,...
Wrapping up 2023 with some noteworthy medicines, law and policy developments
Welcome to our 2023 end-of-the-year blog, our annual and highly-biased run-through of notable access to medicines events of the year that is about to...
World Health Organization Members ask for more time to solve difficult negotiations on access...
World Health Organization member states will propose to continue negotiations on a critical annex to the Pandemic Agreement, after being unable to bridge key...
Time to put a stop to the abuse of orphan drug regulation- the latest...
Today, the Dutch Medical Journal (Nederlands Tijdschrift voor Geneeskunde) reported on the case of lutetium-octreotaat, a cancer drug developed by researchers in the Dutch...
2018 Round-up of Noteworthy Medicines Law and Policy Events
We are reaching the end of 2018: Time for our end-of-the-year roundup of some significant developments in medicines law and policy.
January
The Chilean parliament started...
Delinkage: New proposal offers a promising way forward on access, benefit sharing during pandemics
Members of the World Health Organization (WHO) last week picked up the task of navigating an unwieldy negotiation on a Pathogen Access and Benefit...
ML&P’s Comments to the Intergovernmental Negotiating Body (INB) on the Zero Draft of the...
These remarks were delivered on the occasion of the fourth meeting of the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement...
Wrapping up 2019 – Noteworthy Medicines Law and Policy Events
2019 had its share of noteworthy medicines law and policy events. It was also a year that saw eye-popping new levels of pharmaceutical pricing....
The new EU compulsory licensing regime needs to allow the export of medicines
Guest author Olga Gurgula is a Senior Lecturer in Intellectual Property Law at Brunel Law School, Brunel University London.
A war-weary Ukraine critically depends on the support of...